Bioinformatic detection of E47, E2F1 and SREBP1 transcription factors as potential regulators of genes associated to acquisition of endometrial receptivity

Alejandro Tapia1*, Cristian Vilos2, Juan Carlos Marín3, Horacio B Croxatto2,4, Luigi Devoto1,5

Abstract

Background: The endometrium is a dynamic tissue whose changes are driven by the ovarian steroidal hormones. Its main function is to provide an adequate substrate for embryo implantation. Using microarray technology, several reports have provided the gene expression patterns of human endometrial tissue during the window of implantation. However it is required that biological connections be made across these genomic datasets to take full advantage of them. The objective of this work was to perform a research synthesis of available gene expression profiles related to acquisition of endometrial receptivity for embryo implantation, in order to gain insights into its molecular basis and regulation.

Methods: Gene expression datasets were intersected to determine a consensus endometrial receptivity transcript list (CERTL). For this cluster of genes we determined their functional annotations using available web-based databases. In addition, promoter sequences were analyzed to identify putative transcription factor binding sites using bioinformatics tools and determined over-represented features.

Results: We found 40 up- and 21 down-regulated transcripts in the CERTL. Those more consistently increased were C4BPA, SPP1, APOD, CD55, CFD, CLDN4, DKK1, ID4, IL15 and MAP3K5 whereas the more consistently decreased were OLFM1, CCNB1, CRABP2, EDN3, FGFR1, MSX1 and MSX2. Functional annotation of CERTL showed it was enriched with transcripts related to the immune response, complement activation and cell cycle regulation. Promoter sequence analysis of genes revealed that DNA binding sites for E47, E2F1 and SREBP1 transcription factors were the most consistently over-represented and in both up- and down-regulated genes during the window of implantation.

Conclusions: Our research synthesis allowed organizing and mining high throughput data to explore endometrial receptivity and focus future research efforts on specific genes and pathways. The discovery of possible new transcription factors orchestrating the CERTL opens new alternatives for understanding gene expression regulation in uterine function.

Background

The human endometrium is a complex tissue whose cyclic regulation is mainly driven by the changing pattern of the ovarian steroidal hormones estradiol (E₂) and progesterone (P₄) [1]. The main function of the endometrium is to provide receptive substrate at the appropriate time for blastocyst implantation. Although it is non-adhesive to embryos throughout most of the menstrual cycle [2] the action of P₄ on an E₂-primed endometrium induces a certain gene expression profile that is favorable for blastocyst adhesion during a restricted period of time known as the ‘window of implantation’ [3,4]. In women, this maternally directed receptive phase appears to be of approximately 5 days’
duration, from day 20 to day 24 of a 28-days menstrual cycle [5]. The molecular basis of the window of implantation in human endometrium is beginning to be unrevealed and a number of biochemical markers for uterine receptivity have been proposed [3,6].

Microarrays analysis, an assay that is used to measure the level of mRNA expression of thousands of genes in a group of cells [7], enables discovery of genes or pathways likely to be involved in a biological process. This approach has been used to broadly characterize the molecular bases of endometrial function in women, by determining the gene expression profiles corresponding to each endometrial phase during the menstrual cycle [8-10]. In addition, it has been used to specifically investigate the acquisition of endometrial receptivity to embryo implantation during spontaneous cycles [11-15].

Since changes in the endometrium toward acquisition of receptivity are mainly driven by progesterone (P4) [16,17], two strategies have been used for gene discovery during spontaneous menstrual cycles. These are based on the comparison of the endometrial transcriptome under peak P4 circulating levels (days 19-23, window of implantation) compared to the endometrial gene expression profiles obtained under absent (days 8-11, proliferative phase) [11,12] or low (days 15-17, early secretory phase) [13-15,18,19] serum P4.

Although DNA microarrays are a powerful tool for gene discovery, there are several substantial sources of noise in microarray data. Intra- and inter-microarray variations limit the statistical power to discriminate the differentially expressed genes. While validation of microarray data is required to overcome this issue, most reports of endometrial gene expression analysis included validation of only a small number of differentially expressed genes (usually less than 10) by an independent mRNA quantification method (Northern blot, semi-quantitative or quantitative RT-PCR) [20]. Integration and cross-validation of data sets about endometrial gene expression profiles produced by different groups could increase confidence in gene expression results for many more genes than is tractable with classical validation [21,22] and should provide the up- and down-regulated genes that together orchestrate the acquisition of the receptive phenotype of the endometrium. Such exploration and integration could help researchers to obtain a comprehensive view of existing data and better prioritize experimental efforts.

Transcriptional regulatory mechanisms are crucial for temporal and spatial gene expression. These mechanisms are mediated by a set of transcription factors (TFs), proteins which have the ability to bind to a specific region on the gene (known as motifs or transcription factor binding sites (TFBS)), to regulate transcription. It is thought that co-expression of genes frequently arises from transcriptional co-regulation. As co-regulated genes share some similarities in their regulatory mechanism, possibly at transcriptional level, their promoter regions may contain common regulatory regions that are binding sites for transcription regulators [23]. Given a cluster of endometrial regulated genes with similar expression profiles, the characterization of their regulatory regions is a fundamental step toward understanding the largely unexplored networks of gene regulation in this complex tissue responsible for their coordinated behavior. Computation biology of gene regulation offers several bioinformatic tools developed for the prediction of TFBS within a specific regulatory DNA sequence [24]. Given a set of co-regulated transcripts, *in silico* predictions of TFBS in their regulatory regions offers a unique opportunity to identify novel components, leading to the formulation of transcriptional regulatory networks hypotheses that can be further tested in the wet laboratory.

The aim of this study was to increase our understanding of endometrial receptivity to embryo implantation, by performing a research synthesis of the publicly available DNA microarray data. The first objective was to determine genes consistently reported in the literature as either up- or down-regulated from pre receptive to the receptive endometrium. The second objective was to identify possible TFs that may mediate the regulation of endometrial gene expression, by analyzing the *cis*-regulatory sequences of genes sharing a common regulatory behavior.

**Methods**

**Integration and cross-validation of microarrays data**

The available data sets comparing endometrial gene expression profiles from the proliferative vs. mid secretory phase [11,12] and from early secretory vs. mid secretory phase [9,13-15,19] were analyzed (Table 1). The UniGene key identifier (cluster ID) for each differential expressed transcript was obtained from the SOURCE [25], NetAffx [26] and UniGene [27] databases. Each UniGene entry is a set of transcript sequences that appear to come from the same transcription locus (gene or expressed pseudogene) and was used for cross-referencing transcripts amongst databases. The information from each database was imported into Microsoft Access® software and used as a relational database to determine transcripts that show consistent differential expression under similar experimental conditions. Those having a similar transcriptional response (up- or down-regulation) in at least 4 reports for increased and 3 for decreased transcripts were considered biologically relevant and included in a list we have designated the ‘consensus endometrial receptivity transcript list’ (CERTL). The difference in threshold for considering down-regulated transcripts is because the study...
Table 1 Endometrial gene expression reports performed at the time of implantation in human using DNA microarray

| Study       | First sample (day of cycle, number of samples) | Second sample (day of cycle, number of samples) | Microarrays platform | Fold-change cut-off value | N° of up-regulated transcripts | N° of down-regulated transcripts |
|-------------|-----------------------------------------------|-----------------------------------------------|----------------------|--------------------------|-------------------------------|-------------------------------|
| Kao et al. 2002 [11] | Proliferative phase (8-11, n = 4) | Mid-secretory (21-23, n = 7) | Affymetrix Hu95A | ≥2.0 | 156 | 377 |
| Canon et al. 2002 [13] | Early-secretory (15-17, n = 5*) | Mid-secretory (20-22, n = 3*) | Affymetrix Hu95A | ≥2.0 | 323 | 370 |
| Borwitzer et al. 2003 [12] | Proliferative phase (9-11, n = 5*) | Mid-secretory (19-21, n = 5*) | Affymetrix Hu95A-E | ≥2.0 | 90 | 46 |
| Riesewijk et al. 2003 [14] | Early-secretory (15, n = 5) | Mid-secretory (20, n = 5) | Affymetrix Hu95A | ≥3.0 | 153 | 58 |
| Mirkin et al. 2005 [15] | Early-secretory (16, n = 3) | Mid-secretory (21, n = 5) | Affymetrix HG_U95Av2 | ≥2.0 | 49 | 58 |
| Talib et al. 2006 [9] | Early-secretory (16, n = 3) | Mid-secretory (21, n = 5) | Affymetrix HG_U95Av2 | ≥1.5 | 1415 | 1463 |
| Haouzi et al. 2009* [18] | Early-secretory (16, n = 31) | Mid-secretory (20, n = 31) | Affymetrix HG_U133 plus 2.0 | ≥2.0 | 945 | 67 |

* = pooled samples, † = day the cycle not specified, ‡ = reports only the top 20 up-regulated genes as supplementary data, timing of endometrial biopsies based on first day of menses and not confirmed, possible endometrial pathologies were not excluded.

from Haouzi et al. 2009 [18] does not disclose the decreased transcripts.

Functional clustering

Those up- and down-regulated genes from the CERTL were submitted to web-based databases for functional annotation analysis in order to gain an in-depth understanding of the biological themes in the CERTL. DAVID (Database for Annotation, Visualization and Integrated Discovery) [28] and GATHER (Gene Annotation Tool to Help Explain Relationships) [29] webtools were used for this purpose. Both services extract the biological meaning of submitted genes by retrieving their functional annotations from the Kyoto Encyclopedia of Genes and Genomes (KEGG) [30], Biocarta pathways [31] and Gene Ontology (GO) [32] databases.

TFBS detection in promoter regions of genes associated to endometrial receptivity

We firstly examined the promoter region of our genes of interest defined as the region proximal to the transcription-start site of genes transcribed by RNA polymerase II. For a systematic search for potential TFBS, we used the following approaches and platforms to increase the power of our results:

MotifScanner. We used the stand-alone version of MotifScanner [33] that searches for potential TFBSs in a set of sequences using all the TRANSFAC vertebrate position-weigh matrices (PWMs) [34]. The information of TFBS obtained from MotifScanner was sent to the software TOUCAN [23] for determination of PWMs that were significantly over-represented.

Over-represented Transcription Factor Binding Site Prediction Tool (OTFBS). This web-tool [35,36] searches for potential TFBSs based on the TRANSFAC PWMs using the MatInspector algorithm [37] and determines over-represented motifs in regulatory sequences.

The Transcription Element Listening System (TELiS). The TELiS database [38,39] uses the TRANSFAC and JASPAR [40] PWMs in order to detect potential TFBS. It uses the MatInspector algorithm through the Java application PromoterScan [38] and identifies over-represented motifs.

GATHER. This database [29] searches for potential TFBS using TRANSFAC 8.2 PWMs [41,42] and identifies statically over-represented TFBS.

Results

Identification of genes associated to endometrial receptivity

We intersected the lists of regulated genes reported in studies using microarrays analysis of endometrial receptivity for determining those consistently regulated across different reports. As expected the number of coincident genes was small, considering the number of genes comprising each list. We identified 40 up-regulated genes in at least four of seven reports (Table 2) and 21 down-regulated genes present in at least three of six studies considered (Tables 3), collectively denominated CERTL. The most consistent up-regulated genes were C4BPA, SPP1, APOD, CD55, CFD, CLDN4, DKK1, ID4, IL15 and MAP3K5; whereas OLFM1, CCNB1, CRABP2, EDN3, FGF1, MSX1 and MSX2 were the most consistently down-regulated in endometrial tissue for the acquisition of receptivity to embryo implantation.

Functional associations of transcripts from CERTL

To gain further understanding of the potential functional roles of regulated transcripts present in CERTL we obtained the functional annotations from each gene
Table 2: Up-regulated genes contained in the consensus endometrial receptivity transcripts list (CERTL) based on published reports about human endometrial receptivity using microarray analysis

| UniGene ID | Gene Symbol | Gene Title                                                                 | Kao et al. (2002) | Carson et al. (2002) | Borthwick et al. (2003) | Riesewijk et al. (2003) | Mirkin et al. (2005) | Talbi et al. (2006) | Haouzi et al. (2009) |
|------------|-------------|-----------------------------------------------------------------------------|-------------------|----------------------|--------------------------|--------------------------|--------------------|---------------------|---------------------|
| Hs.1012    | C4BPA       | complement component 4 binding protein, alpha                              | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.313     | SPP1        | secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation) | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.52555   | APOD        | apolipoprotein D                                                            | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.126517  | CD55        | Decay accelerating factor for complement                                     | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.155597  | CFD         | complement factor D (adipsin)                                               | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.647036  | CLDN4       | claudin 4                                                                   | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.40499   | DK1         | dickkopf homolog 1 (Xenopus laevis)                                         | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.519601  | ID4         | Inhibitor of DNA binding 4, dominant negative helix-loop-helix protein       | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.654378  | IL15        | interleukin 15                                                              | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.186486  | MAP3K5      | mitogen-activated protein kinase kinase 5                                   | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.511605  | ANXA2       | annexin A2                                                                  | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.422986  | ANXA4       | annexin A4                                                                  | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.524224  | C1R         | complement component 1, r subcomponent                                      | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.80409   | GADD45A     | growth arrest and DNA-damage-inducible, alpha                               | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.386567  | GBP2        | guanylate binding protein 2, interferon-inducible                            | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.183109  | MAOA        | monoamine oxidase A                                                         | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.532325  | PAEP        | progestagen-associated endometrial protein (glycodelin)                      | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.384598  | SERPING1    | serpin peptidase inhibitor, clade G (C1 inhibitor), member 1, (angioedema, hereditary) | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.1584    | COMP        | cartilage oligomeric matrix protein                                         | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.558314  | CP          | ceruloplasmin (ferroxidase)                                                  | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.368912  | DPP4        | dipeptidyl-peptidase 4 (CD26, adenosine deaminase complexing protein 2)      | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.446392  | DYNLT3      | Dynemin, light chain, Tctex-type 3                                          | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.198862  | FBLN2       | fibulin 2                                                                   | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.433300  | FCER1G      | Fc fragment of IgE, high affinity, l, receptor for, gamma polypeptide        | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.432132  | GOS2        | G0/G1switch 2                                                               | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.2681    | GAST        | gastrin                                                                     | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.616962  | GDF15       | growth differentiation factor 15                                             | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.105806  | GNLY        | granulysin                                                                  | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.386793  | GPX3        | glutathione peroxidase 3 (plasma)                                            | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.497636  | LAMB3       | laminin, beta 3                                                             | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.433391  | MT1G        | Metallothionein-IG                                                          | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.262857  | PRUNE2      | Prune homolog 2 (Drosophila)                                                 | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.50223   | RBP4        | retinol binding protein 4, plasma                                            | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.654444  | S100A4      | S100 calcium binding protein A                                              | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
| Hs.2962    | S100P       | S100 calcium binding protein P                                               | ↑                 | ↑                    | ↑                        | ↑                        | ↑                  | ↑                   | ↑                   |
and determined the enriched processes from two different web-based tools. The up-regulated transcript list was consistently enriched with transcripts related to the immune response and complement activation whereas the down-regulated transcript list was enriched with transcripts related to cell cycle regulation (Tables 4 and 5).

### Identification of consensus sequences for TFBS sites of CERTL
We hypothesized that genes showing a common regulatory behavior may also share common regulatory mechanisms such as TFBSs in their respective promoter regions. To identify these possible common regulatory patterns that should be over-represented in the CERTL, we took advantage of several publicly available bioinformatics tools. The potential TFBS were detected in a first step, and then those statistically over-represented in our endometrial gene cluster were determined. The results are listed in Table 6 for up- and down-regulated transcripts respectively. Interestingly, DNA binding sites for E47, Sterol Regulatory Element Binding Protein 1

### Table 2: Up-regulated genes contained in the consensus endometrial receptivity transcripts list (CERTL) based on published reports about human endometrial receptivity using microarray analysis (Continued)

| UniGene ID | Gene Symbol | Gene Title | Kao *et al.* (2002) | Carson *et al.* (2002) | Borthwick *et al.* (2003) | Riesewijk *et al.* (2003) | Mirkin *et al.* (2005) | Talbi *et al.* (2006) |
|------------|-------------|------------|---------------------|------------------------|--------------------------|--------------------------|------------------------|-----------------------|
| Hs.517070  | SLPI        | secretory leukocyte peptidase inhibitor | ↑↑↑                  | ↑↑↑                         | ↑↑↑                         | ↑↑↑                         | ↑↑↑                         | ↑↑↑                         |
| Hs.517033  | TGM2        | transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase) | ↑↑↑                  | ↑↑↑                         | ↑↑↑                         | ↑↑↑                         | ↑↑↑                         | ↑↑↑                         |
| Hs.525607  | TNFAIP2     | tumor necrosis factor, alpha-induced protein 2 | ↑↑↑                  | ↑↑↑                         | ↑↑↑                         | ↑↑↑                         | ↑↑↑                         | ↑↑↑                         |
| Hs.695930  | VCAN        | versican   | ↑↑↑                  | ↑↑↑                         | ↑↑↑                         | ↑↑↑                         | ↑↑↑                         | ↑↑↑                         |
| Hs.2157    | WAS         | Wiskott-Aldrich syndrome (eczema-thrombocytopenia) | ↑↑↑                  | ↑↑↑                         | ↑↑↑                         | ↑↑↑                         | ↑↑↑                         | ↑↑↑                         |

*Upward arrows indicate up-regulation of the respective transcript.*

### Table 3: Down-regulated genes contained in the consensus endometrial receptivity transcripts list (CERTL) based on published reports about human endometrial receptivity using microarray analysis

| UniGene ID | Gene Symbol | Gene Title | Kao *et al.* (2002) | Carson *et al.* (2002) | Borthwick *et al.* (2003) | Riesewijk *et al.* (2003) | Mirkin *et al.* (2005) | Talbi *et al.* (2006) |
|------------|-------------|------------|---------------------|------------------------|--------------------------|--------------------------|------------------------|-----------------------|
| Hs.522484  | OLFM1       | olfactomedin 1 | ↓↓↓                  | ↓↓↓                         | ↓↓↓                         | ↑↑↑                         | ↓↓↓                         | ↓↓↓                         |
| Hs.23960   | CCNB1       | cyclin B1  | ↓↓↓                  | ↓↓↓                         | ↑↑↑                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         |
| Hs.405662  | CRABP2      | cellular retinoic acid binding protein 2 | ↓↓↓                  | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         |
| Hs.1408    | EDN3        | endothelin 3 | ↓↓↓                  | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         |
| Hs.264887  | FGFR1       | fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome) | ↓↓↓                  | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         |
| Hs.424414  | MSX1        | msh homeobox 1 | ↓↓↓                  | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         |
| Hs.89404   | MSX2        | msh homeobox 2 | ↓↓↓                  | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         |
| Hs.523852  | CCND1       | cyclin D1  | ↓↓↓                  | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         |
| Hs.524947  | CDC20       | cell division cycle 20 homolog (S. cerevisiae) | ↓↓↓                  | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         |
| Hs.1594    | CENPA       | centromere protein A | ↓↓↓                  | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         |
| Hs.83758   | CKS2        | CDC28 protein kinase regulatory subunit 2 | ↓↓↓                  | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         |
| Hs.530904  | CSRP2       | cysteine and glycine-rich protein 2 | ↓↓↓                  | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         |
| Hs.367725  | GATA2       | GATA binding protein 2 | ↓↓↓                  | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         |
| Hs.596913  | HPGD        | hydroxyprostaglandin dehydrogenase 15- (NAD) | ↓↓↓                  | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         |
| Hs.654504  | IHH         | Indian hedgehog homolog (Drosophila) | ↓↓↓                  | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         |
| Hs.438720  | MCM7        | Minichromosome maintenance complex component 7 | ↓↓↓                  | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         |
| Hs.75823   | MLT11       | Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 11 | ↓↓↓                  | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         |
| Hs.143751  | MMP11       | matrix metallopeptidase 11 (stromelysin 3) | ↓↓↓                  | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         |
| Hs.2256    | MMP7        | Matrix metalloproteinase 7 | ↓↓↓                  | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         |
| Hs.658169  | SFRP4       | secreted frizzled-related protein 4 | ↓↓↓                  | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         |
| Hs.182231  | TRH         | thyrotropin-releasing hormone | ↓↓↓                  | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         | ↓↓↓                         |

*Downward arrows indicate down-regulation of the respective transcript.*

---

Tapia et al. Reproductive Biology and Endocrinology 2011, 9:14
http://www.rbej.com/content/9/1/14
Page 5 of 14
Table 4 Functional annotation clusters for up- and down-regulated transcripts from CERTL obtained through GATHER webtool

| Database               | Functional annotation                                      | number of genes | p Value  |
|------------------------|------------------------------------------------------------|-----------------|----------|
| **up-regulated transcripts**                                                                                      |                 |          |
| Gene Ontology          | response to stimulus                                       | 16              | <0.0001  |
| Gene Ontology          | response to biotic stimulus                                | 12              | <0.0001  |
| Gene Ontology          | defense response                                           | 11              | <0.0001  |
| Gene Ontology          | immune response                                            | 10              | <0.0001  |
| Gene Ontology          | response to stress                                         | 9               | 0.0001   |
| Gene Ontology          | complement activation, classical pathway                   | 4               | <0.0001  |
| KEGG Pathway           | Complement and coagulation cascades                        | 4               | 0.0002   |
| **down-regulated transcripts**                                                                                  |                 |          |
| Gene Ontology          | morphogenesis                                              | 10              | 0.0001   |
| Gene Ontology          | cytokinesis                                                | 4               | 0.0001   |
| Gene Ontology          | skeletal development                                       | 4               | 0.0001   |
| Gene Ontology          | development                                                | 12              | 0.0002   |
| KEGG Pathway           | cell cycle                                                 | 4               | 0.0002   |

Enriched functional annotations found in GATHER (Table 4) and DAVID (Table 5) appear in bolded style.

Table 5 Functional annotation clusters for up- and down-regulated transcripts from CERTL obtained through DAVID webtool

| Database               | Functional annotation                                      | number of genes | p Value  |
|------------------------|------------------------------------------------------------|-----------------|----------|
| **up-regulated transcripts**                                                                                      |                 |          |
| GOTERM_CC_FAT          | extracellular region                                       | 22              | <0.0001  |
| SP_PIR_KEYWORDS        | signal                                                     | 22              | <0.0001  |
| UP_SEQ_FEATURE         | signal peptide                                             | 22              | <0.0001  |
| GOTERM_BP_FAT          | defense response                                           | 9               | <0.0001  |
| GOTERM_BP_FAT          | positive regulation of immune response                    | 7               | <0.0001  |
| GOTERM_BP_FAT          | inflammatory response                                      | 7               | <0.0001  |
| GOTERM_BP_FAT          | immune effector process                                    | 6               | <0.0001  |
| GOTERM_BP_FAT          | complement activation                                      | 5               | <0.0001  |
| GOTERM_BP_FAT          | immunoglobulin mediated immune response                    | 5               | <0.0001  |
| GOTERM_BP_FAT          | lymphocyte mediated immunity                               | 5               | <0.0001  |
| GOTERM_BP_FAT          | activation of immune response                              | 5               | <0.0001  |
| KEGG_PATHWAY           | Complement and coagulation cascades                        | 5               | <0.0001  |
| SP_PIR_KEYWORDS        | complement pathway                                         | 4               | <0.0001  |
| GOTERM_BP_FAT          | response to steroid hormone stimulus                       | 4               | 0.0068   |
| GOTERM_BP_FAT          | cell cycle                                                 | 7               | 0.0038   |
| **down-regulated transcripts**                                                                                  |                 |          |
| GOTERM_BP_FAT          | response to steroid hormone stimulus                       | 4               | 0.0068   |
| SP_PIR_KEYWORDS        | cell cycle                                                 | 6               | 0.00045  |
| KEGG_PATHWAY           | cell cycle                                                 | 4               | 0.0038   |
| GOTERM_BP_FAT          | cell division                                              | 5               | 0.0028   |
| GOTERM_BP_FAT          | cell cycle                                                 | 7               | 0.0038   |
| GOTERM_BP_FAT          | regulation of cell cycle                                   | 6               | 0.00047  |
| SP_PIR_KEYWORDS        | developmental protein                                      | 6               | 0.0041   |
| UP_SEQ_FEATURE         | metal ion-binding site: Zinc                               | 3               | 0.0053   |

Enriched functional annotations found in GATHER (Table 4) and DAVID (Table 5) appear in bolded style.
(SREBP1) and E2F1 were the most consistently over-represented and present in both up- and down-regulated transcripts. The number of increased genes with predicted TFBS for E2F1, SREBP1 and E47 was at least 20, 13 and 7 respectively in a total of 40. Of 21 decreased genes the number of transcripts with predicted TFBS was at least 14, 2 and 3 respectively. Other TFs over-represented were MEF2, FREAC2 and ARNT.

**Discussion**

Scientific knowledge of how endometrial receptivity is regulated is fundamental for the understanding of the mechanisms that govern embryonic implantation. The availability of public datasets related to global endometrial gene regulation during the acquisition of the receptive phenotype, provides a tool for the analysis of regulation of gene expression using bioinformatics tools. Using DNA microarrays analysis, several approaches have been used for determining the genes of uterine receptivity assessing the endometrium in different physiological [9,11-15,18,43], pathological [44-48] or intervened conditions [49,50]. We here analyzed seven reports of endometrial gene expression profiling during spontaneous cycles: Carson et al. [13], Kao et al. [11], Borthwick et al. [12], Riesewijk et al. [14], Mirkin et al. [15], Talbi et al. [9] and Haouzi et al. [18]. Since the number of endometrial samples analyzed in each of these studies was limited, the question arises as to whether the groups investigated were representative of the population. This is a major concern for any statistical analysis. Therefore we considered all studies together in a research synthesis to provide a larger sample size thus consolidating the selection of actual regulated transcripts in the endometrium. A first step was to associate probes and available annotations in the reports that belong to the same UniGene cluster (i.e. with same UniGene ID), and then proceed to further comparisons to identify common transcripts that are similarly regulated during the window of implantation. Previous partial analyses [15,43,51-53] found very few transcripts to be

| Tool for TFBS analysis | Transcription factor name | TFBS matrix | p Value | Tool for TFBS analysis | Transcription factor name | TFBS matrix | p Value |
|------------------------|----------------------------|-------------|---------|------------------------|----------------------------|-------------|---------|
| MotifScanner           | E47                        | TRANSFAC    | 0.008   | MotifScanner           | E47                        | TRANSFAC    | 0.002   |
|                        | MEF2                       | TRANSFAC    | 0.002   |                        | SREBP1                     | TRANSFAC    | 0.007   |
|                        | SREBP1                     | TRANSFAC    | 0.007   |                        | ARNT                       | TRANSFAC    | 0.001   |
| TELIS                  | PBX1                       | TRANSFAC    | 0.0001  | TELIS                  | ARNT                       | TRANSFAC    | <0.0001 |
|                        | AP1                        | TRANSFAC    | 0.0005  |                        | HNF1                       | TRANSFAC    | 0.007   |
|                        | E1V1                       | TRANSFAC    | 0.002   |                        | HNF-1                      | TRANSFAC    | 0.007   |
|                        | SOX5                       | TRANSFAC    | 0.003   | OTFBS                  |                           |             |         |
|                        | Sox-5                      | JASPAR      | 0.0031  |                        | BR-C Z1                    | TRANSFAC    | <0.0001 |
|                        | Pbx1                       | JASPAR      | 0.007   |                        | BR-C Z4                    | TRANSFAC    | 0.004   |
| FREAC-2                | JASPAR                     | 0.007      |         |                        | HFH-2                      | TRANSFAC    | <0.0001 |
|                        | SOX-9                      | JASPAR      | 0.008   |                        | HFH-3                      | TRANSFAC    | <0.0001 |
| OTFBS                  | GCN4                       | TRANSFAC    | 0.001   |                        | FOX2                       | TRANSFAC    | <0.0001 |
|                        | CP2                        | TRANSFAC    | 0.007   | GATHER                 | NFY                        | TRANSFAC    | 0.004   |
|                        | Ik-2                       | TRANSFAC    | <0.0001 |                        | E2F1                       | TRANSFAC    | 0.006   |
|                        | Bcd                        | TRANSFAC    | <0.0001 |                        |                            |             |         |
|                        | ARP-1                      | TRANSFAC    | <0.0001 |                        |                            |             |         |
|                        | MEF-2                      | TRANSFAC    | 0.005   |                        |                            |             |         |
|                        | cap                        | TRANSFAC    | 0.004   |                        |                            |             |         |
|                        | E47                        | TRANSFAC    | 0.002   |                        |                            |             |         |
|                        | SREBP-1                    | TRANSFAC    | <0.0001 |                        |                            |             |         |
| GATHER                 | SRF                        | TRANSFAC    | 0.001   |                        |                            |             |         |
|                        | NRF2                       | TRANSFAC    | 0.002   |                        |                            |             |         |
|                        | E2F1                       | TRANSFAC    | 0.002   |                        |                            |             |         |
|                        | FREAC2                     | TRANSFAC    | 0.003   |                        |                            |             |         |
|                        | HEB                        | TRANSFAC    | 0.004   |                        |                            |             |         |
|                        | ELK1                       | TRANSFAC    | 0.005   |                        |                            |             |         |

Transcription factors predicted by more than one analysis tool appear in bolded style.
consistently regulated. In our study we found 61 transcripts regulated in the same direction in the endometrium during the window of implantation; 40 were up-regulated in at least 4 of 7 studies and 21 were down-regulated in at least 3 of 6 reports analyzed.

The relatively small number of consistently regulated transcripts identified could be explained by the differences in the study design, number of samples included and the methodology used for data analysis. However, other factors should be considered when interpreting gene expression analyses related to endometrial receptivity. Importantly, the reports included here, all used RNA extracted from whole endometrial biopsies, tissue that comprises a number of different cell types, including epithelial (luminal and glandular), stromal fibroblasts, endothelial cells, vascular smooth muscle cells and lymphoid cells. Hence the endometrial changes induced by E2 and P4 result from the differential response of each cell type to the same hormones. A clear example is the down regulation of the PR during the secretory phase in endometrial epithelial cells but not in the stromal compartment [54]. Microdissection of cell subpopulations (for example, with laser capture [55]) may disclose the actual gene expression profiles of each cell subpopulations within the tissue context. In addition, any biopsy sample may not represent the complete endometrium since microenvironments occur within this tissue. Nevertheless gene expression profiling of endometrial biopsies during the window of implantation is one of the most promising strategies for gene discovery related to uterine receptivity.

The intersection of gene lists performed in the present study showed that most consistently increased transcripts during the window of implantation were C4BPA, SPP1, APOD, CD55, CFD, CLDN4, DKK1, ID4, IL15 and MAP3K5 whereas OLFM1, CCNB1, CRABP2, EDN3, FGFR1, MSX1 and MSX2 were the most consistently decreased. However, correlation of transcript abundance change with changes in the corresponding protein, followed by functional testing of the biological effect of that protein, is necessary to confirm the biological significance of the microarray changes.

The functional annotations of up-regulated genes within the CERTL showed a significant association to the immune response and complement activation. Most of these genes belong to the innate immune system, which is the immunological first line of defense that provides an immediate response through its ability to distinguish between ‘infectious non-self’ and ‘non-infectious self’ [56]. Therefore, innate immunity regulation in the endometrium is of fundamental significance for establishing a microenvironment that will provide adequate tolerance to the implanting embryo [57]. Regarding complement system regulatory proteins, their possible roles and expression levels in the endometrium throughout the normal menstrual cycle have been reported [58-62]. Most of these studies show an increase of complement-regulatory molecules during the secretory phase in human endometrium [58,61,62] in line with the increased mRNA levels of the complement system molecules C4b-binding protein (C4BP) and adipsin (complement component factor D, CFD) from the CERTL. It is postulated that the complement system might be conferring immunity to the uterine cavity, defending it against bacterial infection. In this sense, C4BP may provide a protective role to the embryo where an increased expression of an inhibitor of complement system activation could reduce the chance of a misdirected complement attack to the embryo (which is considered as a semiallograft). Indeed, C4BPA transcript levels are abnormally decreased in the endometrium during the receptive phase in women with endometriosis [44,63], implantation failure [46] and unexplained recurrent abortion [64], suggesting it may have a role in embryo implantation. By contrast, adipsin may have a non-complement function in the female reproductive tract as suggested for other complement-molecules [60]. Adipsin is necessary for the production of oviduct-derived embryotrophic factor-3 (ETF-3) [65,66] which stimulates embryo development [67,68]. Thus up-regulation of adipsin in human endometrium may assist the embryo during the implantation process as shown for other chemokines in the endometrium [69].

Several down-regulated genes within CERTL are associated with cell cycle regulation, including cyclin B1 (CCNB1) the most consistently down-regulated gene. CCNB1 binds to p34 (cdc2) to form the mitosis-promoting factor during G2 phase [70,71]. In human secretory phase endometrium, CCNB1 is decreased compared to the proliferative phase [72,73] supporting the microarray data used to construct the CERTL. Moreover, in endometrial cell cultures, P4 decreases the expression of CCNB1, inhibits cell proliferation and induces apoptosis, suggesting that cyclin B1 may play an important role in proliferation and differentiation of the endometrial tissue under steroidal regulation.

Cellular retinol binding protein-2 (CRABP2) is a cytosolic protein that binds retinoic acid (RA) with high affinity [74]. The CRABP2 transcript has been reported to decrease from the proliferative to the secretory phase in human endometrium [75], which is in line with the microarrays reports used for constructing our CERTL. The physiological effects of RA are mediated by members of two families of nuclear receptors [76,77] and they all have been detected by immunohistochemistry in human endometrium throughout the phases of the menstrual cycle [78] in epithelial and stromal cells. The fact that CRABP2 decreases in human endometrium at the
time of embryo implantation might suggest that RA signaling is required to be silenced, since it shuttles RA to the RA receptors in the cell nucleus [74,78]. In the mouse uterus, CRABP2 decreases around the time of embryo implantation [79] whereas P4 induces the expression of cyp26a1, the enzyme responsible for RA catabolism in mouse uterine epithelial cells [80,81]. Knock down of cyp26a1 in mouse uterus decreases embryo implantation rate [82]. In addition, in human secretory endometrium, cyp26a1 mRNA level is ~20 times higher than in the proliferative phase [83]. Since the action of RA is essential for endometrial stromal cell decidualization [79] silencing of RA signaling during the window of implantation might prevent precocious decidualization of stromal cells that could compromise endometrial receptivity.

The cytokine endothelin-3 (EDN3) and fibroblast growth factor receptor-1 (FGFR1) were among the transcripts consistently down-regulated in the endometrium during the window of implantation. There is abundant evidence showing that both endometrial receptivity and blastocyst implantation are regulated by cytokines and growth factors [84]. Immunoreactive pro-endothelin-3 has been described in human endometrium in luminal and glandular epithelia; however cycle-dependent regulation of this molecule is not clear [85]. Its action in the human endometrium is suggested to be in paracrine vasoactive control of the uterine vascular bed [86]. However this cytokine has many other functions such as proliferation and development of several cell types [87-90]. In the mouse oviduct, EDN3 signaling has been associated with the regulation of transcripts related to TGFβ, IL-10, and C/EBP [91]. Its functional role in the human endometrium and the effects of its down-regulation during the window of implantation has yet to be determined. FGFR1 and its ligand FGF-2 have also been described in human endometrium [92-95]. Immunoreactive FGFR1 and its transcript are significantly higher in proliferative that in secretory human endometrium [93,94] supporting the down-regulation of this transcript included in the CERTL. However, not all studies have reported such endometrial regulation [95]. FGF-2 promotes endometrial stromal proliferation [94,96] and ovarian steroid hormones modulate its synthesis and function in endometrial cells [96,97]. The functional relevance of FGFR1 down-regulation in endometrial receptivity remains to be elucidated.

With regard to the TFs present in the CERTL, we found the inhibitor of DNA binding 4 (ID4) up-regulated and MSX-1 and -2 down-regulated. In animal models, uterine MSX-1 and -2 are down-regulated by P4 [98] or during embryo implantation [99-101]. Constant expression of Msx1 in the infertile Llf/- mice uterus further supports a role for MSX-1 down-regulation in endometrial receptivity [100]. ID4 TF is a member of a family of inhibitor of DNA binding proteins (Id) that has been associated with cell proliferation and differentiation [102-105]. Its regulatory effect in human endometrium is unknown. Many other TFs associated with endometrial regulation [106-120] have provided insights into the molecular basis of gene regulation for endometrial function in response to sex steroid hormones. We reasoned that the cluster of regulated genes derived from microarray experiments related to endometrial receptivity (i.e. CERTL) would allow a different strategy for TF discovery, namely comparative promoter analysis. This is based on the hypothesis that genes showing a common regulatory behavior may also share common regulatory mechanisms such as TFBSs in their respective promoter regions. Interestingly, we found that E47, E2F1 and SREBP1 are common TFBSs for up- and down-regulated transcripts from CERTL so it is likely that they orchestrate the changes in transcript profile for endometrial receptivity. None of these three TFs have been described in normal human endometrium in the context of their regulation during the menstrual cycle, in response to steroidal hormones or a regulatory role on uterine function. However, there is no guarantee that the revealed TFBS are indeed functional in the context of regulatory regions, hence biological verification is required.

The E2F1 TF belongs to the E2F family [121] and displays properties of both an oncogene (induction of proliferation) and tumor suppressor (induction of apoptosis) [122,123]. E47 is a TF that belongs to the class I bHLH proteins, also known as E proteins [124] which form homo- or hetero-dimers and bind to specific DNA sequences [125]. Sterol regulatory element-binding protein 1 (SREBP1) is a membrane-bound TFs that belongs to a family of basic helix-loop-helix-leucine zipper (bHLHLZ) TFs [126]. Upon activation, SREBP1 translocates into the nucleus where it binds to sterol regulatory sites located in the promoter regions of genes involved in cholesterol homeostasis and transport [127,128] such as the steriodogenic acute regulatory protein (StAR), a key regulator of steriodogenesis [129]. Function of bHLH TFs such as E47 can be blocked by Inhibitor of DNA binding (Id) TFs [130,131]. In addition, SREBP1 as a member of bHLHLZ family, may also be subjected to regulation by Id proteins [132]. In the CERTL ID4 transcript was up-regulated in the receptive endometrium: as a consequence E47 and SREBP-1 TFs may be less available for binding to DNA in target sequences and direct co-regulated transcripts. Interestingly, the TF E2F1 is involved in the transcriptional control of Id4 gene expression [133], supporting our bioinformatics findings of overrepresented TFBSs.

It is well known that P4 is essential for the establishment and maintenance of pregnancy in the women and
in this sense the study of its actions in the uterus has been focused on changes in gene expression [134,135]. Responses to $P_4$ in reproductive tissues occur by the activation of classical nuclear $P_4$ receptors (PRA and B), which upon binding with their ligand, function as TFs regulating gene expression [136]. In addition, many transcriptional actions of $P_4$ require interactions with corepressors and coactivators [137-139]. However, $P_4$ may also act in the uterus through at least two families of nonclassical membrane progestin receptors [140,141]. Hence the genomic and non-genomic pathways may interact and integrate to ultimately affect endometrial gene expression. Interestingly, two of the endometrial transcripts more consistently up-regulated during the mid-secretory phase, APOD and SPP1, do not display progesterone response elements in their cis-regulatory sequences [12,15] suggesting that $P_4$ induction is not directly mediated by the ligand-bound PR. Interestingly both APOD and SPP1 genes display TFBS for E2F1 in their upstream regulatory sequences. In breast cancer cells, $P_4$ up-regulates the expression of E2F1 and hence indirectly affects transcription of classic E2F1 target genes [115]. Such regulation of E2F1 induced by progestins has been shown to be multimodal since ligand-bound PR can regulate its transcription directly but also indirectly through other molecules to achieve further progesterin-mediated regulation of E2F1 expression [142]. Whether E2F1 along with E47 and SRBP1 are also mediating the $P_4$ transcriptional regulation in the endometrium for acquisition of receptivity has yet to be determined.

Identification of the CERTL and the possible regulatory TFs in the present research synthesis should not be viewed as an end in itself. Their real value increases only as these results move through to biological validation, ranging from the numerical verification of expression levels with alternative techniques, to ascertaining the actual regulatory role of the TFs in the endometrial transcriptional networks. Finally, for several transcripts contained in the CERTL, biological knowledge is completely lacking in relation to endometrial physiology, so extensive research is required to better understand the mechanisms underlying endometrial receptivity.

**Conclusion**

In conclusion, a CERTL comprised of 61 transcripts consistently regulated in human endometrium during the receptive period for embryo implantation has been identified in this study. These transcripts are mainly involved in immune response, complement activation and cell cycle regulation; suggesting that these biological processes are associated with the acquisition of the receptive phenotype. Finally, TFBS for E47, SREBP1 and E2F1 were over-represented in the regulatory region of genes from CERTL, suggesting that they may be mediating the effects of the ovarian steroid hormones in the endometrial transcriptional regulation. Biological validation of such bioinformatic predictions will shed light on the transcriptional networks associated to uterine receptivity for embryo implantation. Moreover, this knowledge can potentially be applied to improve fertility in infertile patients.

**Abbreviations**

- bHLH: basic helix-loop-helix transcription factors; bHLHLZ: basic helix-loop-helix-leucine zipper; C/EBP: CAAT/enhancer-binding proteins; C4BP: C4-binding protein; CCNB1: cyclin B1; CERTL: consensus endometrial receptivity transcript list; CFD: complement component factor D; CLDN4: claudin-4; CRABP2: cellular retinol binding protein-2; DAVID: database for annotation, visualization and integrated discovery; DNA: deoxyribonucleic acid; E2: estradiol; EDN3: endothelin-3; EDNRB: endothelin receptor type B; ETF-3: oviduct-derived embryotrophic factor-3; FGF: fibroblast growth factor; FGFRI: fibroblast growth factor receptor-1; GATHER: gene annotation tool to help explain relationships; GO: gene ontology; ID: inhibitor of DNA binding proteins; ID4: inhibitor of DNA binding 4; IL-10: interleukin-10; KEGG: Kyoto encyclopedia of genes and genomes; LH: luteinizing hormone; LIF: leukemia inhibitory factor; mRNA: messenger ribonucleic acid; OTFBS: over-represented transcription factor binding site prediction tool; P2: progesterone; RA: retinoic acid; RT-PCR: reverse transcription-polymerase chain reaction; SRE: sterol regulatory element; SREBP1: sterol regulatory element binding protein 1; TELIS: the transcription element listening system; TF: transcription factor; TFBS: transcription factor binding site; TGFβ: transforming growth factor-β.

**Acknowledgements**

We thank Reinaldo González-Ramos and M. Cecilia Johnson (IDMI, Universidad de Chile, Santiago, Chile) for their helpful comments and critical review of the article. We thank also Lois Salamonsen (Prince Henry’s Institute, Melbourne, Australia) for her comments and suggestions. This study was supported by FONDECYT 3090075 and FONDAP-15010006. A.T. is supported by PBCT-PSD51(IDIMI).

**Authors’ contributions**

AT conceived of the study, participated in its design, carried out the bioinformatic analyses and helped to draft the manuscript. CV participated in the creation and intersection of database. JCM participated in its design and data analysis. HBC participated in the coordination and helped to draft the manuscript. LD contributed to data analysis and helped to draft the manuscript. All authors read and approved the final manuscript.

**Competing interests**

The authors declare that they have no competing interests.

**Received: 3 November 2010 Accepted: 27 January 2011**

**References**

1. Wynn RM: Cyclic and gestational changes. New York: Plenum Publishing Corp, 1989.
2. Psychos A: Uterine receptivity for nidation. Ann N Y Acad Sci 1986, 476:36-42.
3. Guadice LC: Potential biochemical markers of uterine receptivity. Hum Reprod 1999, 14(Suppl 2):3-16.
4. Salamonsen LA, Nie G, Dimitriadis E, Robb L, Findlay JK: Genes involved in implantation. Reprod Fert Dev 2001, 13(1):41-49.
5. Navot D, Scott RT, Drosch K, Veeck LL, Liu HC, Rosenwaks Z: The window of embryo transfer and the efficiency of human conception in vitro. Fertil Steril 1991, 55(1):114-118.
6. Hoozemans DA, Schatz R, Lambalk CB, Homburg R, Hompes PG: Human embryo implantation: current knowledge and clinical implications in assisted reproductive technology. Reprod Biomed Online 2004, 9(6):692-715.

7. Schena M, Shalon D, Davis RW, Brown PO: Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995, 270(5235):467-470.

8. Ponnampalam AP, Weston GC, Trajstman AC, Susil B, Rogers PA: Molecular classification of human endometrial cycle stages by transcriptional profiling. Mol Hum Reprod 2004, 10(12):879-895.

9. Talbi S, Hamilton AE, Vo KC, Tulac S, Overgaard MT, Dziouc C, Le Shay N, Nezhat CR, Kampo R, Lessey BA et al: Molecular phenotyping of human endometrium distinguishes menstrual cycle phases and underlying biological processes in normo-ovarian women. Endocrinology 2006; 147(3):1097-1121.

10. Puryaardea C, Dassen H, Klomp J, Dunselman G, Kamps R, Dies J, Ederveen A, de Goey A, Groothuis P: Oestrogen-modulated gene expression in the human endometrium. Cell Mol Life Sci 2006; 62(2):239-250.

11. Kao LC, Tulac S, Lobo S, Imani B, Yang JP, Germainy A, Osteen K, Taylor RN, Lessey BA, Giudice LC: Global gene profiling in human endometrium during the window of implantation. Endocrinology 2002, 143(6):2119-2138.

12. Borthwick JM, Charnock-Jones DS, Tom BD, Hull ML, Terney R, Phillips SC, Smith SK: Determination of the transcript profile of human endometrium. Mol Hum Reprod 2003, 9(1):19-33.

13. Carson DD, Lagow E, Thathiah A, Al-Shami R, Farach-Carson MC, Vernon M, Yuan L, Fritz MA, Lessey SA: Changes in gene expression during the early to mid-luteal (receptive phase) transition in human endometrium detected by high-density microarray screening. Mol Hum Reprod 2002, 8(9):871-879.

14. Resevjik A, Martin J, van Os R, Horcajadas JA, Polman J, Pellicer A, Mosсел Simon S, Simon C: Gene expression profiling of human endometrial receptivity on days LH+2 versus LH+7 by microarray technology. Mol Hum Reprod 2003, 9(5):253-264.

15. Mirkin S, Arslan M, Churikov D, Corica A, Diaz JI, Williams S, Bocca S, Oehminger S: In search of candidate genes critically expressed in the human endometrium during the window of implantation. Hum Reprod 2005, 20(8):2104-2117.

16. Connelly OM, Mulac-Jericevic B, DeMayo F, Lydon JP, O'Malley BW: Reproductive functions of progesterone receptors. Recent Prog Horm Res 2002, 57:539-555.

17. Spicer TE, Bazer FW: Biology of progesterone action during pregnancy recognition and maintenance of pregnancy. Front Biosci 2002, 7:1870-1898.

18. Haouzi D, Assou S, Mahmoud K, Tondeur S, Remé T, Hedon B, De Vos J, Hamamah S: Gene expression profile of human endometrial receptivity: comparison between natural and stimulated cycles for the same patients. Hum Reprod 2009, 24(6):1426-1445.

19. Haouzi D, Mahmoud K, Fourati M, Bendhaou K, Dechadu H, De Vos J, Remé T, Dewavry D, Hamamah S: Identification of new biomarkers of human endometrial receptivity in the natural cycle. Hum Reprod 2009, 24(1):198-205.

20. White CA, Salamonsen LA: A guide to issues in microarray analysis: application to endometrial biology. Reproduction 2005, 130(1):1-13.

21. Kummerer P, van Berkum NL, Vilo I, Bjima T, Donders R, Brazma A, Holstege FC: Protein interaction verification and functional annotation by integrated analysis of genome-scale data. Mol Cell 2002, 9(5):1133-1143.

22. Rhodes DR, Barretto TR, Rubin MA, Ghosh D, Chinnaiyan AM: Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 2002, 62(13):4277-4283.

23. Aerts S, Thijs G, Goessens B, Staes M, Moreau Y, De Moor B: Toucan: deciphering the cis-regulatory logic of coregulated genes. Nucleic Acids Res 2003, 31(1):1753-1764.

24. Wasserman WW, Sandelin A: Applied bioinformatics for the identification of regulatory elements. Nat Rev Genet 2004, 5(4):267-287.

25. SOURCE search [http://source.stanford.edu/].

26. NetAffx™ Analysis Center. [http://www.affymetrix.com/index/index.affx].

27. UniGene home. [http://www.ncbi.nlm.nih.gov/unigene].

28. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lemppicki RA: DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003, 4(5):P3.
growth inhibition, G2/M cell cycle arrest, and apoptosis in human endometrial cell. Reprod Biol Endocrinol 2009, 7:144.
74. Gugure V: Retinoid acid receptors and cellular retinoid binding proteins: complex interplay in retinoid signaling. Endocr Rev 1994, 15(1):61-79.
75. Prentice A, Matthews CL, Thomas EJ, Redfern CP. The expression of retinoic acid receptors in cultured human endometrial stromal cells and effects of retinoid acid. Hum Reprod 1992, 7(5):692-700.
76. Kumarendran MK, Loughney AD, Prentice A, Thomas EJ, Redfern CP. Nuclear retinoid receptor expression in normal human endometrium throughout the menstrual cycle. Mol Hum Reprod 1996, 2(12):123-129.
77.懵敏-Kay GA, Ward SJ. Retinoids and mammalian development. Int Rev Cytol 1999, 188:73-131.
78. Itk K, Suzuki T, Moriya T, Utsunomiya H, Sugawara A, Konno R, Sato S, Sasano H. Retinoid receptors in the human endometrium and its disorders: a possible modulator of 17 beta-hydroxy-steroid dehydrogenase. J Clin Endocrinol Metab 2001, 86(6):2721-2727.
79. Zheng WL, Ong DE. Spatial and temporal patterns of expression of cellular retinol-binding protein and cellular retinoid acid-binding proteins in rat uterus during early pregnancy. Biol Reprod 1998, 58(4):969-970.
80. Jeong JW, Lee KY, Kwak I, White LD, Hilsenbeck SG, Lydon JP, DeMayo FJ. Identification of murine uterine genes regulated in a ligand-dependent manner by the progesterone receptor. Endocrinology 2005, 146(8):3490-3505.
81. Fritzsch B, Vermon J, Neumann U, Schmidt A, Schweigert FJ, Dolle P, Ruhl R. Regulation of expression of the retinoic acid metabolizing enzyme CYP26A1 in uteri of ovariectomized mice after treatment with ovarian steroid hormones. Mol Reprod Dev 2007, 74(2):258-264.
82. Han BC, Xia HF, Sun J, Yang Y, Peng JP. Retinoid acid-metabolizing enzyme cytochrome P450 26A1 (cyto6a1) is essential for implantation: functional study of its role in early pregnancy. J Cell Physiol 2010, 223(2):471-479.
83. Deng L, Shipley GL, Loose-Mitchell DS, Stancel GM, Ricker JH, Davies PD. Coordinate regulation of the production and signaling of retinoid acid by estrogen in the human endometrium. J Clin Endocrinol Metab 2003, 88(5):2157-2163.
84. Guzeloglu-Kayisli O, Kayisli UA, Taylor HS. The role of growth factors and cytokines during implantation: endocrine and paracrine interactions. Semin Reprod Med 2009, 27(1):62-79.
85. Cameron IT, Plumptre C, Champeney R, van Papendorp C, Ashby MJ, Davenport AP. Identification of endothelin-1, endothelin-2 and endothelin-3 in human endometrium. J Reprod Fertil 1993, 98(1):251-255.
86. Cameron IT, Davenport AP, van Papendorp C, Barker PJ, Hukstons NS, Gilmour RS, Brown MJ, Smith SK. Endothelin-like immunoreactivity in human endometrium. J Reprod Fertil 1992, 95(2):623-628.
87. Shimii O, Kimura S, Sawamura T, Sugita Y, Yoshizawa T, Uchiyama Y, Yasagisawa M, Goto K, Masaki T, Kanazawa I. Endothelin-3 is a novel neuropeptide: isolation and sequence determination of endothelin-1 and endothelin-3 in porcine brain. Biochem Biophys Res Commun 1989, 161(1):587-593.
88. Matsumoto H, Suzuki N, Onda H, Fujino M. Abundance of endothelin-3 in rat intestine, pituitary gland and brain. Biochem Biophys Res Commun 1989, 164(1):74-80.
89. Baynash AG, Hossack K, Giard A, Richardson JA, Emoto N, Hammer RE, Giguere V. Endothelin-1 and endothelin-2 receptors in normal human endometrium and their interplay in endometrial stromal cells. Endocrinology 2006, 147(9):3736-3746.
90. Montani D, Souza R, Binkert C, Fischli W, Simonneau G, Clozel M, Bridges PJ. Identification of a novel role for endothelins within the oviduct. Endocrinology 2010, 151(6):2858-2867.
91. Ferraresi RA, Charnock-Jones DS, Prentice A, Thomas EJ, Smith SK. Immunohistochemical localization of acidic and basic fibroblast growth factors in normal human endometrium and endometriosis and the detection of their mRNA by polymerase chain reaction. Hum Reprod 1993, 8(1):11-16.
92. Anania CA, Stewart EA, Quade BJ, Hill JA, Nowak RA. Expression of the fibroblast growth factor receptor in women with leiomyomas and abnormal uterine bleeding. Mol Hum Reprod 1997, 3(8):685-691.
94. Sangha RK, Li XF, Shams M, Ahmed A: Fibroblast growth factor receptor-1 is a critical component for endometrial remodeling: localization and expression of basic fibroblast growth factor and FGF-R1 in human endometrium during the menstrual cycle and decreased FGF-R1 expression in menorrhagia. Lab Invest 1997, 77(4):389-402.

95. Moller B, Rasmussen C, Lindblom B, Olsson M: Expression of the angiogenic growth factors VEGF, FGF-2, EGF and their receptors in normal human endometrium during the menstrual cycle. Mol Hum Reprod 2001, 7(1):65-72.

96. Inveen, JC, Urga-VKH, Eckert RL: Sex steroids and growth factors differentially regulate the growth and differentiation of cultured human endometrial stromal cells. Endocrinology 1991, 129(5):2385-2392.

97. Presta M: Sex hormones modulate the synthesis of basic fibroblast growth factor in human endometrial adenocarcinoma cells: implications for the neovascularization of normal and neoplastic endometrium. J Cell Physiol 1998, 173(3):559-567.

98. Satterfield MC, Song G, Hayashi K, Bazer FW, Spencer TE: The Id proteins and angiogenesis. J Cell Sci 2001, 124(2):335-345.

99. Daikoku T, Song H, Guo Y, Riesewijk A, Mosselman S, Das SK, Day SK: Uterine Mx1 and Wnt4 signaling becomes aberrant in mice with the loss of leukemia inhibitory factor or Hoxa-10: evidence for a novel cytokine-homeobox-Wnt signaling in implantation. Mol Endocrinol 2004, 18(5):1238-1250.

100. Manouss-Arta N, Sandra O, Aubert J, Degrellle S, Evrard RE, Giraud-Delville C, Heyman Y, Gallo L, Hue I, Yang X, et al: Endometrium as an early sensor of in vitro embryo manipulation technologies. Proc Natl Acad Sci USA 2009, 106(14):5687-5692.

101. Norton JD: ID-helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. J Cell Sci 2000, 113(Pt 22):3897-3905.

102. Pierce AM, Schneider-Broussard R, Gimenez-Conti IB, Russell JL, Conti CJ, Nissen RM, et al: Id proteins at the cross-road of E2F-1: balancing life and death. J Cell Sci 2001, 114(Pt 22):3897-3905.

103. Yokota Y: Id and development. Oncogene 2001, 20(58):8290-8298.

104. Lasorella A, Li Q, Tavolani A: Id proteins at the cross-road of development and cancer. Oncogene 2001, 20(58):8326-8333.

105. Benezra R, Davis RL, Lockshon D, Turner DL, Weintraub H: The Id proteins and angiogenesis. Oncogene 2001, 20(58):8334-8341.

106. Maldonado V, Castilla JA, Martinez L, Herruzo A, Concha A, Fontes J, Veldscholte J, van Doorn HC, Ewing PC, Kim JJ, Grootegoed JA, et al: Id: a negative regulator of helix-loop-helix DNA binding factor-alpha-induced cyclooxygenase-2 overexpression in eutopic endometrium of women with endometriosis by stromal cell culture through nuclear factor-kappaB activation. J Reprod Med 2009, 54(10):625-630.

107. Kilpatrick LM, Kola I, Salamonsen LA: Functional differentiation of uterine stromal cells involves cross-regulation between bone morphogenetic protein 2 and Kruppel-like factor (KLF) family members KLF9 and KLF13. Endocrinology 2010, 151(7):3596-3601.

108. Martin R, Taylor MB, Krikun G, Lockwood C, Akbas GE, Taylor HS: Id proteins inhibit Stat5, and its enhancement of PRL expression in human endometrial stromal cells. Endocrinology 2002, 143(1):123-131.

109. Du H, Sano J, Taylor HS: HOXA10 inhibits Kruppel-like factor 9 expression in the human endometrial epithelium. Biol Reprod 2010, 82(6):205-211.

110. Kim Y, Kim JY, Kim MR, Hwang KJ, Chang DY, Jeon MK: Tumor necrosis factor-alpha-induced cyclooxygenase-2 overexpression in eutopic endometrium of women with endometriosis by stromal cell culture through nuclear factor-kappaB activation. Br J Obstet Gynaecol 2009, 116(1):57-63.

111. Lynch VJ, Schneider-Broussard R: Role of E2F in cell cycle control and cancer. Front Biosci 1998, 3:4447-4448.

112. La Thangue NB: The Yin and Yang of E2F-1: balancing life and death. Nat Cell Biol 2003, 5(7):576-587.

113. Pierce AM, Schneider-Broussard R, Gimenez-Conti IB, Russell JL, Conti CJ, Johnson DG: E2F1 has both oncosgenic and tumor-suppressive properties in a transgenic model. Mol Cell Biol 1999, 19(9):6408-6414.

114. Murre C, McCaw PS, Baltimore D: A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell 1989, 56(5):777-783.

115. Berezna R, Davis RL, Lassar A, Tapsott C, Thayer M, Lockshon D, Weintraub H: Id: a negative regulator of helix-loop-helix DNA binding proteins. Control of terminal myogenic differentiation. Ann N Y Acad Sci 1990, 599:1-11.

116. Yokoyama C, Wang X, Briggs MR, Admon A, Wu J, Hua X, Goldstein JL, Brown MS, Goldstein JL: The yin and yang of E2F-1: balancing life and death. Oncogene 2001, 20(11):8326-8333.

117. Pabona JM, Zeng Z, Simmen FA, Simmen RC: Functional differentiation of uterine stromal cells involves cross-regulation between bone morphogenetic protein 2 and Kruppel-like factor (KLF) family members KLF9 and KLF13. Endocrinology 2010, 151(7):3596-3601.

118. Strakova Z, Reed J, Ihnatovych I: Human transcriptional coactivator with PDZ-binding motif (TAZ) is downregulated during decidualization. Biol Reprod 2010, 82(6):1112-1118.

119. Cook IH, Evans JJ, Maldonado-Perez D, Crutchley HO, Sales KJ, Jabbour HN: Prokineticin-1 (PROK1) modulates interleukin (IL-11) expression via prokineticin receptor 1 (PROKR1) and the calcineurin/NFAT signalling pathway. Mol Hum Reprod 2010, 16(3):158-169.

120. Wang Y, Hanfl-Moghaddam P, Hanekamp EE, Kloosterboer HJ, Franken P, Veldscholte J, van Doorn HC, Ewing PC, Kim JJ, Grootegoed JA, et al: Progesterone inhibition of Wnt/beta-catenin signaling in normal endometrium and endometrial cancer. Clin Cancer Res 2005, 11(18):5784-5790.

121. Johnson DG, Schneider-Broussard R: Role of E2F in cell cycle control and cancer. Front Biosci 1998, 3:4447-4448.

122. Endometrial stromal cells and myometrial smooth muscle cells. Lab Invest 2001, 83(11):1230-1236.

123. Pohnke Y, Schneider-Merck T, Fahnenstich J, Kempf R, Christian M, Milde- Langosch K, Brossmann J, Gellersen B: Wild-type p53 protein is up-regulated upon cyclic adenosine monophosphate-induced differentiation of human endometrial stromal cells. J Clin Endocrinol Metab 2004, 89(10):5233-5244.

124. Pabona JM, Zeng Z, Simmen FA, Simmen RC: Functional differentiation of uterine stromal cells involves cross-regulation between bone morphogenetic protein 2 and Kruppel-like factor (KLF) family members KLF9 and KLF13. Endocrinology 2010, 151(7):3596-3601.

125. Strakova Z, Reed J, Ihnatovych I: Human transcriptional coactivator with PDZ-binding motif (TAZ) is downregulated during decidualization. Biol Reprod 2010, 82(6):1112-1118.

126. Yokoyama C, Wang X, Briggs MR, Admon A, Wu J, Hua X, Goldstein JL, Brown MS, Goldstein JL: The yin and yang of E2F-1: balancing life and death. Oncogene 2001, 20(11):8326-8333.

127. Pabona JM, Zeng Z, Simmen FA, Simmen RC: Functional differentiation of uterine stromal cells involves cross-regulation between bone morphogenetic protein 2 and Kruppel-like factor (KLF) family members KLF9 and KLF13. Endocrinology 2010, 151(7):3596-3601.
133. Fontemaggi G, Dell’Orso S, Trisciuglio D, Shay T, Melucci E, Faiz F, Terrenato I, Mottolese M, Muti P, Domany E, et al: The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat Struct Mol Biol 2009, 16(10):1086-1093.

134. Giudice LC: Genes associated with embryonic attachment and implantation and the role of progesterone. J Reprod Med 1999, 44(2 Suppl):165-171.

135. Tabibzadeh S. Molecular control of the implantation window. Hum Reprod Update 1998, 4(5):465-471.

136. O’Malley BW, Tsai MJ: Molecular pathways of steroid receptor action. Biol Reprod 1992, 46(2):163-167.

137. Wagner BL, Norris JD, Knotts TA, Weigel NL, McDonnell DP: The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor. Mol Cell Biol 1998, 18(3):1369-1378.

138. Archer TK, Deross BJ, Fryer CJ: Chromatin modulation of glucocorticoid and progesterone receptor activity. Trends Endocrinol Metab 1997, 8(10):384-390.

139. McKenna NJ, O’Malley BW: Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 2002, 108(4):465-474.

140. Fernandes MS, Pierron V, Michalovich D, Astle S, Thornton S, Peltoketo H, Lam EW, Gellersen B, Huhtaniemi I, Allen J, et al: Regulated expression of putative membrane progestin receptor homologues in human endometrium and gestational tissues. J Endocrinol 2005, 187(1):89-101.

141. Zhang L, Kanda Y, Roberts DJ, Ecker JL, Losel R, Wehling M, Peluso JJ, Pru JK: Expression of progesterone receptor membrane component 1 and its partner serpine 1 mRNA binding protein in uterine and placental tissues of the mouse and human. Mol Cell Endocrinol 2008, 287(1-2):81-89.

142. Wade HE, Kobayashi S, Eaton ML, Jansen MS, Lobenhofer EK, Lupien M, Geistlinger TR, Zhu W, Nevins JR, Brown M, et al: Multimodal regulation of E2F1 gene expression by progestins. Mol Cell Biol 2010, 30(8):1866-1877.

do:10.1186/1477-7827-9-14
Cite this article as: Tapia et al: Bioinformatic detection of E47, E2F1 and SREBP1 transcription factors as potential regulators of genes associated to acquisition of endometrial receptivity. Reproductive Biology and Endocrinology 2011 9:14.